Tiaa Fsb Sells 5,916 Shares of Halozyme Therapeutics, Inc. (HALO)

TIAA FSB cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,084 shares of the biopharmaceutical company’s stock after selling 5,916 shares during the quarter. TIAA FSB’s holdings in Halozyme Therapeutics were worth $871,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Sageworth Trust Co increased its stake in Halozyme Therapeutics by 4,200.0% during the 1st quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 2,100 shares in the last quarter. American Century Companies Inc. increased its stake in Halozyme Therapeutics by 108.9% during the 4th quarter. American Century Companies Inc. now owns 416,996 shares of the biopharmaceutical company’s stock worth $6,101,000 after purchasing an additional 217,379 shares in the last quarter. Geode Capital Management LLC increased its stake in Halozyme Therapeutics by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 1,520,657 shares of the biopharmaceutical company’s stock worth $22,247,000 after purchasing an additional 76,753 shares in the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $23,682,000. Finally, Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 36.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,097,080 shares of the biopharmaceutical company’s stock worth $16,050,000 after purchasing an additional 294,909 shares in the last quarter. Hedge funds and other institutional investors own 83.33% of the company’s stock.

Halozyme Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $16.22. 790,871 shares of the company’s stock traded hands, compared to its average volume of 763,694. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.95 and a quick ratio of 2.71. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -28.96 and a beta of 1.79. Halozyme Therapeutics, Inc. has a fifty-two week low of $13.24 and a fifty-two week high of $19.96.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $56.95 million for the quarter, compared to analysts’ expectations of $67.80 million. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. The company’s quarterly revenue was up 84.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) EPS. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

HALO has been the subject of several research reports. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Tuesday, January 29th. Cantor Fitzgerald set a $24.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Thursday, February 28th. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. ValuEngine cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. Finally, TheStreet downgraded Halozyme Therapeutics from a “c” rating to a “d” rating in a report on Tuesday, March 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $20.17.

TRADEMARK VIOLATION NOTICE: This piece was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/tiaa-fsb-sells-5916-shares-of-halozyme-therapeutics-inc-halo.html.

Halozyme Therapeutics Company Profile

There is no company description available for Halozyme Therapeutics Inc

Featured Article: Percentage Gainers

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.